Shares of Clinical Data Inc. skyrocketed 67.5 percent Monday after the FDA's late Friday approval of vilazodone in major depressive disorder quieted skeptics and positioned the Newton, Mass.-based firm as a potential takeover target. Read More
Inovio Pharmaceuticals Inc. expects to gross $24.3 million in an offering of 21.1 million shares of common stock packaged with 10.5 million warrants priced at $1.15 a unit, 11.5 percent below the stock's closing price of $1.30 last Friday. The Blue Bell, Pa.-company said it expects to net $23 million. Read More
Most people's bucket lists include things like traveling to exotic places and reuniting with long lost friends. But philanthropists have harder decisions to make. In 2007, when Denny Sanford donated $400 million to the Sioux Valley Health System, of Sioux Falls, S.D., he turned to a panel of experts to decide how best to use the gift. His requirements were simple. The project should address a disease of relevance to the population of the region, and should cure it within the 73-year-old philanthropist's lifetime. Read More
Polyplus-transfection SA, of Strasbourg, France, said it has granted Roche Glycart AG, a Swiss biotechnology company fully owned by Roche, a nonexclusive license to use polyethylenimine (PEI) for in vitro transfection applications for research purposes. The license will enable Roche Glycart AG to use PEI in its research to produce antibody-based products. Read More
Raptor Pharmaceutical Corp., of Novato, Calif., completed enrollment in a Phase III study of its delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis. Read More
